Tuesday, February 14, 2023
EndoStream Medical today announced the first patient enrolled in the TORNADO-US clinical study in the U.S. This study evaluates the Nautilus™ Intrasaccular System, a revolutionary technology designed to treat cerebral aneurysms. The patient was treated at The Mount Sinai Hospital in New York, one of the largest and most respected hospitals in the nation.
"The enrollment of the first patient in the TORNADO-US clinical study is a major milestone for the treatment of cerebral aneurysms," said Chris Kellner, MD, Assistant Professor of Neurosurgery at the Icahn School of Medicine at Mount Sinai and Principal Investigator of the TORNADO-US clinical study. "We are excited to be at the forefront of this innovation."
Tomoyoshi Shigematsu, MD, Assistant Professor of Neurosurgery, Neurology and Radiology at Icahn Mount Sinai and the surgeon who performed this first-in-US case, said "I was impressed by the ease of use and the versatility of the device. The procedure went smoothly and the patient is recovering well."
In addition to the Nautilus Intrasaccular System, the patient was treated with Kaneka i-ED coils, which were used in conjunction with the Nautilus. The Kaneka i-ED coils are a new generation of coils designed for the treatment of cerebral aneurysms and have been shown to provide excellent aneurysm occlusion rates.
Although Drs. Shigematsu and Kellner have no financial interests with EndoStream Medical, other faculty members in the Department of Neurosurgery at Mount Sinai are investors in this private company.
